• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

    2/14/25 1:16:54 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email

    WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange.

    • On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.

    • On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The shares of the Series C have a 7.5% annual dividend and are convertible into shares of common stock after 6 months, at the election of the holder. The Series C is non-voting.

    • On June 11, Tevogen Bio entered into a definitive agreement for up to $50 million in financing, consisting of a $36 million line of credit and a $14 million contingent private placement. The line of credit was available immediately and allows Tevogen Bio to access up to $1 million per month at an annual interest rate of the lower of (a) the daily SOFR plus 2.0% and (b) 7.0%. The private placement is available at the counterparty's option contingent on the Company's share price.

    • On February 15, Tevogen Bio entered into a securities purchase agreement for an $8 million Series A Preferred Stock investment. The investment was made in conjunction with Tevogen Bio's debut as a public company.

    In addition to financing activity from 2024, on January 28, 2025, Tevogen Bio entered into an agreement to receive up to $10 million in grant funding. This grant funding is not dilutive to existing Tevogen Bio shareholders. $2 million was received and an additional $8 million may be provided at a future date based on the grantor's review of the Company's activities.

    "Tevogen Bio's ability to secure strategic financing reflects confidence in our unique, cost-efficient business model, which has the potential to serve as a blueprint for sustainable medical innovation," said Dr. Ryan Saadi, Founder and CEO of Tevogen Bio. "This funding, combined with our disciplined operations and innovative approach, may enable R&D efforts and accelerate advancements in Tevogen.AI. Our mission to develop accessible, personalized T cell therapies that can serve large patient populations without the traditional cost barriers of advanced therapeutics remains clear."

    About Tevogen Bio

    Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements.

    Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

    Forward Looking Statements

    This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen's plans to expand its efforts in artificial intelligence; Tevogen's ability to develop additional product candidates; Tevogen's use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

    Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the "Business Combination") on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC.

    You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

    Contacts

    Tevogen Bio Communications

    T: 1 877 TEVOGEN, Ext 701

    [email protected]



    Primary Logo

    Get the next $TVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    SEC Filings

    See more
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      5/14/25 5:27:46 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tevogen Bio Holdings Inc.

      10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      5/14/25 5:27:11 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      5/7/25 5:03:59 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/29/25 8:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/14/25 1:53:50 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

      WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This announcement coincides with a significant milestone in Tevogen's growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko's focus will include a

      3/26/25 3:12:23 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/14/24 5:29:01 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/12/24 4:28:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

      SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      3/4/24 4:24:14 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Flomenberg Neal sold $253,935 worth of shares (232,968 units at $1.09), decreasing direct ownership by 6% to 3,595,608 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/14/25 9:02:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Flomenberg Neal sold $231,734 worth of shares (211,909 units at $1.09), decreasing direct ownership by 5% to 3,828,576 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/11/25 8:52:08 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Flomenberg Neal sold $250,006 worth of shares (213,817 units at $1.17), decreasing direct ownership by 5% to 4,040,485 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/6/25 9:41:49 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/13/24 4:30:24 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/7/24 4:29:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Tevogen Bio with a new price target

      D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

      3/4/25 8:26:08 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

      WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs. Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation

      5/30/25 11:01:18 AM ET
      $MSFT
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

      WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced a planned expansion of TVGN 489's target population to include patients 65 and older. As previously reported in October 2024, the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expansion aims to broaden the market potential of Tevogen's specialty pharmaceuticals. An updated forecast and the risk adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population.

      5/23/25 3:49:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

      WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that it will provide several updates to stockholders in advance of the Company's upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company's innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization. Ahead of the annual meeting, Tevogen intends to provide information on: Portfolio Assets: The Company will provide an update on its robust portfolio assets of Tevogen Bio Oncology, Tevogen Bio Specialty Care and

      5/22/25 1:21:42 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Financials

    Live finance-specific insights

    See more
    • Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

      WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The

      2/14/25 1:16:54 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

      WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e

      8/22/24 9:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

      WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com

      8/15/24 9:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care